Asthma

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia

Retrieved on: 
Monday, April 1, 2024
Dermatology, Vitiligo, Prurigo nodularis, Patient, Collaboration, Research, Asthma, JAK1, HS, Hidradenitis suppurativa, PN, CMS, Autoimmunity, Pharmaceutical industry

Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.

Key Points: 
  • Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.
  • CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.
  • “We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Herve Hoppenot, Chief Executive Officer, Incyte.
  • Upon approval, povorcitinib is poised to synergize with the innovative drugs in the commercialization stage of our pipeline ILUMETRI (tildrakizumab injection), original drugs including Hirudoid (mucopolysaccharide polysulfate cream) and Aethoxysklerol (polidocanol injection) in terms of our network and market resources, which will help the Product to realize its clinical and commercial value.”
    The transaction is effective immediately upon the execution of the Collaboration and License Agreement.

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease

Retrieved on: 
Tuesday, April 9, 2024
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Development, Risk, Diabetes, Ageing, Chronic obstructive pulmonary disease, Head, RSV, Senior, Asthma, Safety, Vaccine, Person

Adults with certain underlying chronic conditions are at increased risk of developing, and being hospitalized for, RSV-associated LRTD1,2.

Key Points: 
  • Adults with certain underlying chronic conditions are at increased risk of developing, and being hospitalized for, RSV-associated LRTD1,2.
  • However, no RSV vaccines have been approved for use in adults 18 to 59 years of age.
  • The MONeT study was initiated to address this significant unmet need by investigating the immunogenicity and safety of ABRYSVO in adults aged 18 to 59 at increased risk for RSV disease, such as those with asthma, diabetes, and chronic obstructive pulmonary disease.
  • “These encouraging results provide evidence that ABRYSVO can help protect adults with increased risk against RSV-associated illness,” said Annaliesa Anderson, Ph.D., Senior Vice President and Head, Vaccine Research and Development, Pfizer.

Advancing Health Equity Through Pharmacy: New White Paper Explores the Pivotal Role Pharmacists Can Play in Providing Needed Care for Underserved Patients

Retrieved on: 
Tuesday, April 9, 2024
Don Miguel Ruiz, Pharmacist, Health, Health literacy, Doctor of Pharmacy, Patient, Policy, Asthma, Health equity, Physician, Medicine, Pharmaceutical industry

The new paper explores the barriers impacting patient health, particularly for under-resourced patients and those on Medicaid, and how pharmacists can bridge healthcare gaps and improve the health of those individuals.

Key Points: 
  • The new paper explores the barriers impacting patient health, particularly for under-resourced patients and those on Medicaid, and how pharmacists can bridge healthcare gaps and improve the health of those individuals.
  • The report also proposes steps needed to further elevate the role of pharmacists to help reduce disparities by increasing the services and care they can provide.
  • Value-based practices, like AbsoluteCare , that integrate pharmacists into the healthcare team, can improve patient adherence and outcomes in vulnerable populations.
  • "We have seen significant patient improvements when pharmacists intervene and educate our members about their health and treatments," said Mike Radu, CEO, AbsoluteCare.

Two Barrels of Oil Per Day Is All Drillers Extract from Community Wells, Making Case For New Law For $10K Per Day Fine, says Consumer Watchdog

Retrieved on: 
Monday, April 8, 2024
Sentinel, Consumer Watchdog, Health, Risk, School, F-150, Hospital, Research, Cancer, Ford, Birth, Energy Information Administration, Asthma, Aera Energy, California State Assembly, Multimedia, Jamie Court, Oil

"With oil at less than $80 per barrel, oil drillers are putting the health of communities at risk for less than $150 per day."

Key Points: 
  • "With oil at less than $80 per barrel, oil drillers are putting the health of communities at risk for less than $150 per day."
  • FracTracker Alliance found that overall statewide oil production averages 3.3 barrels per day per well based on CalGEM data for 2022.
  • An onshore well that produces between 1,000 and 3,000 barrels of oil a day is considered a good production range .
  • "The average community well's two barrel of oil output is not even enough to fuel four Ford F-150 trucks."

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

Retrieved on: 
Monday, March 25, 2024
I&I, TARC, Atopic dermatitis, Disease, Half-life, Patient, SAN, Heel, IND, Respiratory disease, Asthma, SQ, Clinical trial, Therapy, Safety, Pharmacokinetics, Engineering, Pharmaceutical industry

SAN FRANCISCO and WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), COPD, asthma and other inflammatory and immunology (I&I) indications, today announced that it has initiated dosing of healthy volunteers in its first clinical trial for APG808, a novel subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-4Rα, which is being developed as a treatment for people living with moderate-to-severe COPD, asthma and other I&I diseases.

Key Points: 
  • COPD is a progressive respiratory disease that is estimated to affect approximately 10 percent of the global population 40 years of age and older.
  • Despite recent advancements in COPD treatment, a significant number of people continue to suffer and die from the disease.
  • The APG808 Phase 1 trial is designed as a double-blind, placebo-controlled, first-in-human, single-ascending dose trial in healthy volunteers.
  • Importantly, this points to potentially less frequent dosing for patients with COPD, which could significantly improve quality of life.”

ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Research, Nitrosamine, Anaphylaxis, Symantec Endpoint Protection, Absorption, Human, ARS, MAA, Patent, Caregiver, PD, New Drug Application, SAN, Patient, Adrenaline, Journal, CRL, NDA, American Academy, EMA, Quality of life, Trial of the century, Flare, American College, Investment, Clinical trial, Erythema, Lower respiratory tract infection, Asthma, Body surface area, Itch, Allergy, FDA, AAAAI, Total, Food, Pharmaceutical industry

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the fourth quarter and full year 2023.

Key Points: 
  • In February 2024, ARS Pharma announced the successful completion of the repeat dosing study of neffy in seasonal allergic rhinitis under nasal allergen challenge conditions.
  • R&D Expenses: Research and development expenses were $3.4 million and $20.3 million for the quarter and year ended December 31, 2023, respectively.
  • G&A Expenses: General and administrative expenses were $6.8 million and $47.3 million for the quarter and year ended December 31, 2023, respectively.
  • Net Loss: Net loss was $7.2 million and $54.4 million for the quarter and year ended December 31, 2023, respectively.

TLI Investigator Dr. Nicholas Jenzjowsky Receives NIH/NIAID Grant to Investigate the Neural Regulation of Asthma

Retrieved on: 
Wednesday, March 20, 2024
TLI, Asthma, Research, Hope, Doctor of Philosophy, Allergy, Neuron, Immunoglobulin E, Infection, Pharmaceutical industry

The grant will fund the innovative project "Asthmatic inflammation requires neuronal upregulation of B-cells," which commenced this month and will run until January 2025.

Key Points: 
  • The grant will fund the innovative project "Asthmatic inflammation requires neuronal upregulation of B-cells," which commenced this month and will run until January 2025.
  • This groundbreaking research aims to delve into the complexities of asthma and its symptoms, a major global health concern that requires a deeper understanding of its underlying mechanisms.
  • The innovative nature of this project underscores TLI's commitment to cutting-edge science and the potential impact of the research.
  • It aims to uncover potential drug targets and inform new strategies to mitigate the growing problem of allergic asthma.

AAFA Statement on EPA Cars Rule

Retrieved on: 
Wednesday, March 20, 2024
AAFA, Climate change, Season, Asthma, Light, Policy, Hope, Quality of life, EPA, Pollen, Air pollution, Weather, Renewable energy

Washington, D.C., March 20, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) applauds a new rule by the Environmental Protection Agency (EPA) that will drive America toward a future with zero vehicle emissions.

Key Points: 
  • Washington, D.C., March 20, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) applauds a new rule by the Environmental Protection Agency (EPA) that will drive America toward a future with zero vehicle emissions.
  • The EPA announced final national pollution standards for passenger cars, light-duty trucks, and medium-duty vehicles for model years 2027 through 2032 and beyond.
  • “Transportation-related emissions are a leading contributor to air pollution,” said Kenneth Mendez, president and CEO of AAFA.
  • By reducing emissions from cars and light trucks, the EPA’s new rule will improve the quality of life for the 27 million people in the United States with asthma.

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

Cover the Latest Developments in Allergy and Clinical Immunology at the EAACI Congress 2024 in Valencia, Spain

Retrieved on: 
Tuesday, March 19, 2024
Food, Conjunctivitis, Prevalence, Atopic dermatitis, Data science, Incidence, Patient, Research, Science, Congress, EAACI, Asthma, Physician, Health care, Cochineal

VALENCIA, Spain, March 19, 2024 (GLOBE NEWSWIRE) -- The European Academy of Allergy and Clinical Immunology (EAACI), with a membership of over 16,000 from 125 countries, annually orchestrates its congress to unveil the latest research and innovative advancements in allergy and clinical immunology. We are thrilled to extend a warm invitation to you for the upcoming EAACI Congress 2024, scheduled to take place in Valencia from May 31st to June 3rd, 2024.In a bid to provide you with an immersive experience, we will offer you a dedicated press area where you can schedule interviews with leading physicians and researchers in the field.

Key Points: 
  • VALENCIA, Spain, March 19, 2024 (GLOBE NEWSWIRE) -- The European Academy of Allergy and Clinical Immunology (EAACI), with a membership of over 16,000 from 125 countries, annually orchestrates its congress to unveil the latest research and innovative advancements in allergy and clinical immunology.
  • We are thrilled to extend a warm invitation to you for the upcoming EAACI Congress 2024, scheduled to take place in Valencia from May 31st to June 3rd, 2024.
  • Our venue, Feria de Valencia , is a prestigious convention and exhibition centre known for its modernity and versatility.
  • The Scientific Programme will encompass the entire spectrum of Allergy and Clinical Immunology.